PROGRAM CHAIR

Matthew Matasar, MD
Chief of Blood Disorders
Rutgers Cancer Institute
Professor of Medicine
Rutgers RWJ Medical School
Brunswick, NJ

PROGRAM DESCRIPTION

This enduring program encompasses the management of relapsed/refractory non-Hodgkins lymphoma (NHL) with a new class of therapy—bispecific antibodies. These novel and emerging agents redirect T-cells to attack CD20-positive NHL, resulting in immune-mediated clearance of malignant cells. To ensure safe use of these off-the-shelf therapies, this program will also review best practices for grading and management of potential adverse events, including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS).

TARGET AUDIENCE

This activity is designed to meet the educational needs of hematologists/oncologists practicing and their clinical teams.

LEARNING OBJECTIVES

• Apply approved bsAbs to management plans for patients with R/R NHLs where appropriate
• Analyze clinical studies of recently approved and emerging bsAbs for R/R NHLs
• Implement strategies for the mitigation and management of AEs associated with the use of bsAbs in patients with R/R NHLs
• Establish routine communication across the hematology/oncology care team and with the patient to optimize shared decision making and involvement in overall care plan development

JOINT ACCREDITATION STATEMENT

In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIAN CREDIT DESIGNATION STATEMENT

Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.

NURSES (ANCC) CREDIT DESIGNATION

Med Learning Group designates this activity for a maximum of 1.0 ANCC contact hour.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF FINANCIAL RELATIONSHIPS

All relevant financial relationships have been mitigated.

Content Review

The content of this activity was independently peer reviewed by a physician and nurse reviewer.

Individuals in Control of the Content of the Activity

The individuals in control of the content of this activity reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:

• Matthew Frese, General Manager of Med Learning Group has nothing to disclose.
• Christina Gallo, SVP, Educational Development for Med Learning Group has nothing to disclose.
• Sarah Milano RN. MSN has nothing to disclose.
• A medical reviewer from CME Peer Review LLC, has nothing to disclose.
• Lauren Welch, MA, VP, Outcomes and Accreditation for Med Learning Group has nothing to disclose.
• Michael R. Page, PharmD, RPh Medical Director for Med Learning Group, has nothing to disclose.
• Melissa A. Johnson, Program Director for Med Learning Group has nothing to disclose.
• Millena De Brito, Program Coordinator for Med Learning Group has nothing to disclose.
• Daniel DaSilva, Accreditation and Outcomes Manager for Med Learning Group has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During the course of this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CE credit for this activity.  In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.

DISCLAIMER

Med Learning Group makes every effort to develop CE activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.

For CE questions, please contact Med Learning Group at [email protected]

Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Event staff will be glad to assist you with any special needs (eg, physical, dietary, etc). Please contact Med Learning Group at [email protected]

RELEASED DATE: January 24, 2025
EXPIRATION DATE: January 24, 2026

Copyright © 2025 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.